QQQ   444.84 (+0.00%)
AAPL   170.76 (-1.47%)
MSFT   420.78 (-0.15%)
META   488.94 (-1.00%)
GOOGL   150.75 (-0.08%)
AMZN   180.84 (+0.56%)
TSLA   176.62 (-1.79%)
NVDA   907.43 (+0.55%)
NIO   4.63 (-0.86%)
AMD   181.86 (+1.26%)
BABA   72.56 (+1.35%)
T   17.56 (+0.06%)
F   13.27 (+1.61%)
MU   118.43 (-0.60%)
CGC   9.78 (+2.41%)
GE   175.57 (-2.53%)
DIS   122.69 (+1.41%)
AMC   3.74 (-13.82%)
PFE   27.88 (+0.36%)
PYPL   66.85 (+0.42%)
XOM   115.51 (+0.47%)
QQQ   444.84 (+0.00%)
AAPL   170.76 (-1.47%)
MSFT   420.78 (-0.15%)
META   488.94 (-1.00%)
GOOGL   150.75 (-0.08%)
AMZN   180.84 (+0.56%)
TSLA   176.62 (-1.79%)
NVDA   907.43 (+0.55%)
NIO   4.63 (-0.86%)
AMD   181.86 (+1.26%)
BABA   72.56 (+1.35%)
T   17.56 (+0.06%)
F   13.27 (+1.61%)
MU   118.43 (-0.60%)
CGC   9.78 (+2.41%)
GE   175.57 (-2.53%)
DIS   122.69 (+1.41%)
AMC   3.74 (-13.82%)
PFE   27.88 (+0.36%)
PYPL   66.85 (+0.42%)
XOM   115.51 (+0.47%)
QQQ   444.84 (+0.00%)
AAPL   170.76 (-1.47%)
MSFT   420.78 (-0.15%)
META   488.94 (-1.00%)
GOOGL   150.75 (-0.08%)
AMZN   180.84 (+0.56%)
TSLA   176.62 (-1.79%)
NVDA   907.43 (+0.55%)
NIO   4.63 (-0.86%)
AMD   181.86 (+1.26%)
BABA   72.56 (+1.35%)
T   17.56 (+0.06%)
F   13.27 (+1.61%)
MU   118.43 (-0.60%)
CGC   9.78 (+2.41%)
GE   175.57 (-2.53%)
DIS   122.69 (+1.41%)
AMC   3.74 (-13.82%)
PFE   27.88 (+0.36%)
PYPL   66.85 (+0.42%)
XOM   115.51 (+0.47%)
QQQ   444.84 (+0.00%)
AAPL   170.76 (-1.47%)
MSFT   420.78 (-0.15%)
META   488.94 (-1.00%)
GOOGL   150.75 (-0.08%)
AMZN   180.84 (+0.56%)
TSLA   176.62 (-1.79%)
NVDA   907.43 (+0.55%)
NIO   4.63 (-0.86%)
AMD   181.86 (+1.26%)
BABA   72.56 (+1.35%)
T   17.56 (+0.06%)
F   13.27 (+1.61%)
MU   118.43 (-0.60%)
CGC   9.78 (+2.41%)
GE   175.57 (-2.53%)
DIS   122.69 (+1.41%)
AMC   3.74 (-13.82%)
PFE   27.88 (+0.36%)
PYPL   66.85 (+0.42%)
XOM   115.51 (+0.47%)
NASDAQ:CELC

Celcuity (CELC) Stock Price, News & Analysis

$20.35
+2.19 (+12.06%)
(As of 11:27 AM ET)
Today's Range
$17.67
$20.59
50-Day Range
$14.35
$18.56
52-Week Range
$8.39
$20.59
Volume
152,303 shs
Average Volume
211,141 shs
Market Capitalization
$492.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00

Celcuity MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
67.0% Upside
$30.33 Price Target
Short Interest
Bearish
8.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.03mentions of Celcuity in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$4,952 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.76) to ($2.84) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.34 out of 5 stars

Medical Sector

526th out of 939 stocks

Medical Laboratories Industry

12th out of 20 stocks

CELC stock logo

About Celcuity Stock (NASDAQ:CELC)

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

CELC Stock Price History

CELC Stock News Headlines

Q4 2023 Celcuity Inc Earnings Call
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Recap: Celcuity Q4 Earnings
CELC Apr 2024 20.000 call
Buy Friday, Sell Monday, No Exceptions
Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
Celcuity (NASDAQ: CELC)
See More Headlines
Receive CELC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
3/28/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:CELC
Fax
N/A
Employees
45
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.33
High Stock Price Target
$40.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+47.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-40,370,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.17 per share

Miscellaneous

Free Float
18,322,000
Market Cap
$492.47 million
Optionable
Optionable
Beta
0.74
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Brian F. Sullivan (Age 62)
    Co-Founder, Chairman & CEO
    Comp: $105.77k
  • Dr. Lance G. Laing Ph.D. (Age 62)
    Co-Founder, Chief Science Officer, VP, Secretary & Director
    Comp: $325.38k
  • Ms. Vicky Hahne (Age 58)
    Chief Financial Officer
    Comp: $210k
  • Dr. John R. MacDonald Dabt (Age 69)
    Ph., Ph.D., Senior Vice President of R&D
  • Ms. Sheri Smith
    Acting Head of Clinical Operations
  • Mr. Igor Gorbatchevsky M.D.
    Chief Medical Officer
  • Mr. Eldon C. Mayer III (Age 63)
    M.B.A., Chief Commercial Officer

CELC Stock Analysis - Frequently Asked Questions

Should I buy or sell Celcuity stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CELC shares.
View CELC analyst ratings
or view top-rated stocks.

What is Celcuity's stock price target for 2024?

3 analysts have issued 1 year price objectives for Celcuity's shares. Their CELC share price targets range from $24.00 to $40.00. On average, they expect the company's share price to reach $30.33 in the next year. This suggests a possible upside of 67.0% from the stock's current price.
View analysts price targets for CELC
or view top-rated stocks among Wall Street analysts.

How have CELC shares performed in 2024?

Celcuity's stock was trading at $14.57 at the beginning of the year. Since then, CELC shares have increased by 24.6% and is now trading at $18.16.
View the best growth stocks for 2024 here
.

When is Celcuity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our CELC earnings forecast
.

How were Celcuity's earnings last quarter?

Celcuity Inc. (NASDAQ:CELC) posted its earnings results on Monday, November, 13th. The company reported ($0.83) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by $0.09. During the same quarter in the previous year, the company earned ($0.75) earnings per share.

What other stocks do shareholders of Celcuity own?
When did Celcuity IPO?

Celcuity (CELC) raised $18 million in an initial public offering on Wednesday, September 20th 2017. The company issued 2,000,000 shares at a price of $8.00-$10.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

Who are Celcuity's major shareholders?

Celcuity's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Commodore Capital LP (7.25%), Perceptive Advisors LLC (6.12%), Vanguard Group Inc. (3.39%), Vanguard Group Inc. (3.39%), Northern Trust Corp (0.76%) and PFM Health Sciences LP (0.65%). Insiders that own company stock include Brian F Sullivan, David Dalvey, Richard E Buller and Richard Nigon.
View institutional ownership trends
.

How do I buy shares of Celcuity?

Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CELC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners